[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f5mOwk8zy9a7Duc9WnC2o0cHGvgytIlcuGwaQfN3L3ic":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":57,"rows":64},"State University of New York - Upstate Medical University",[4],155,false,11,4,11854,6,109,[14,16,18,20,22,24,27,29],{"name":15,"count":9},"Obesity",{"name":17,"count":9},"Schizophrenia",{"name":19,"count":9},"Alcohol Dependence",{"name":21,"count":9},"Autism Spectrum Disorder",{"name":23,"count":9},"Borderline Personality Disorder",{"name":25,"count":26},"Pain",3,{"name":28,"count":26},"Dengue",{"name":30,"count":26},"Osteoporosis",[32,37,42,47,52],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT07220031","Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol Assay","2026-05-01","Activated Charcoal",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06611111","Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease","2026-12","Ceftriaxone",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT07373743","Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults","2027-03","Tafenoquine Oral",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT00775476","Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine","2027-03-31","N-acetylcysteine",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT04736953","Sirolimus Treatment Of Patients With SLE","2029-01-01","Sirolimus",[58,59,60,61,62,63],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[65,89,112,135,153,174,208,246,285,310,336,362,388,414,432,450,468,486,514,541,568,592,620,638,656,680,707,725,747,773,791,818,836,861,885,910,948,981,999,1021,1039,1064,1087,1114,1138,1156,1182,1207,1225,1250,1268,1294,1312,1334,1357,1380,1403],{"intervention":56,"totalTrials":66,"cells":67},1,{"EARLY_PHASE1":68,"PHASE1":71,"PHASE2":73,"PHASE3":83,"PHASE4":85,"NA":87},{"trials":69,"activeCount":70},[],0,{"trials":72,"activeCount":70},[],{"trials":74,"activeCount":66,"soonestReadout":55},[75],{"nctId":53,"briefTitle":54,"status":76,"phases":77,"primaryCompletion":55,"completion":55,"start":78,"enrollment":79,"conditions":80,"interventions":82},"NOT_YET_RECRUITING",[60],"2025-01-01",220,[81],"Lupus Erythematosus, Systemic",[56],{"trials":84,"activeCount":70},[],{"trials":86,"activeCount":70},[],{"trials":88,"activeCount":70},[],{"intervention":51,"totalTrials":66,"cells":90},{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":106,"PHASE4":108,"NA":110},{"trials":92,"activeCount":70},[],{"trials":94,"activeCount":70},[],{"trials":96,"activeCount":66,"soonestReadout":50},[97],{"nctId":48,"briefTitle":49,"status":98,"phases":99,"primaryCompletion":50,"completion":100,"start":101,"enrollment":102,"conditions":103,"interventions":105},"ACTIVE_NOT_RECRUITING",[60],"2028-09-30","2022-05-05",290,[104],"Systemic Lupus Erythematosus",[51],{"trials":107,"activeCount":70},[],{"trials":109,"activeCount":70},[],{"trials":111,"activeCount":70},[],{"intervention":41,"totalTrials":66,"cells":113},{"EARLY_PHASE1":114,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":133},{"trials":115,"activeCount":66,"soonestReadout":40},[116],{"nctId":38,"briefTitle":39,"status":117,"phases":118,"primaryCompletion":40,"completion":40,"start":119,"enrollment":120,"conditions":121,"interventions":123},"RECRUITING",[58],"2025-02-03",44,[122],"Post-Treatment Lyme Disease",[41,124],"Dextrose 5%",{"trials":126,"activeCount":70},[],{"trials":128,"activeCount":70},[],{"trials":130,"activeCount":70},[],{"trials":132,"activeCount":70},[],{"trials":134,"activeCount":70},[],{"intervention":124,"totalTrials":66,"cells":136},{"EARLY_PHASE1":137,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":151},{"trials":138,"activeCount":66,"soonestReadout":40},[139],{"nctId":38,"briefTitle":39,"status":117,"phases":140,"primaryCompletion":40,"completion":40,"start":119,"enrollment":120,"conditions":141,"interventions":142},[58],[122],[41,124],{"trials":144,"activeCount":70},[],{"trials":146,"activeCount":70},[],{"trials":148,"activeCount":70},[],{"trials":150,"activeCount":70},[],{"trials":152,"activeCount":70},[],{"intervention":46,"totalTrials":66,"cells":154},{"EARLY_PHASE1":155,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":170,"NA":172},{"trials":156,"activeCount":66,"soonestReadout":45},[157],{"nctId":43,"briefTitle":44,"status":76,"phases":158,"primaryCompletion":45,"completion":45,"start":159,"enrollment":160,"conditions":161,"interventions":163},[58],"2026-05",20,[162],"Pharmacokinetic in Normal Population",[46],{"trials":165,"activeCount":70},[],{"trials":167,"activeCount":70},[],{"trials":169,"activeCount":70},[],{"trials":171,"activeCount":70},[],{"trials":173,"activeCount":70},[],{"intervention":36,"totalTrials":175,"cells":176},2,{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":185,"NA":198},{"trials":178,"activeCount":70},[],{"trials":180,"activeCount":70},[],{"trials":182,"activeCount":70},[],{"trials":184,"activeCount":70},[],{"trials":186,"activeCount":70},[187],{"nctId":188,"briefTitle":189,"status":190,"phases":191,"primaryCompletion":192,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":197},"NCT06219967","Does a Soft Drink Mixture Improve Tolerance of Activated Charcoal in the Adult Poisoned Patient Without Affecting Efficacy","COMPLETED",[62],"2023-03-14","2023-01-04",5,[196],"Overdose",[36,36],{"trials":199,"activeCount":66,"soonestReadout":35},[200],{"nctId":33,"briefTitle":34,"status":76,"phases":201,"primaryCompletion":35,"completion":35,"start":202,"enrollment":203,"conditions":204,"interventions":207},[],"2025-11-15",8,[205,206],"Osmolality Disturbance","Lab Interference",[36],{"intervention":209,"totalTrials":175,"cells":210},"Injectable Naltrexone",{"EARLY_PHASE1":211,"PHASE1":213,"PHASE2":215,"PHASE3":217,"PHASE4":219,"NA":244},{"trials":212,"activeCount":70},[],{"trials":214,"activeCount":70},[],{"trials":216,"activeCount":70},[],{"trials":218,"activeCount":70},[],{"trials":220,"activeCount":70},[221,231],{"nctId":222,"briefTitle":223,"status":224,"phases":225,"primaryCompletion":226,"completion":226,"start":227,"enrollment":160,"conditions":228,"interventions":230},"NCT00461890","Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial","TERMINATED",[62],"2007-12","2006-10",[19,229],"Veterans",[209],{"nctId":232,"briefTitle":233,"status":190,"phases":234,"completion":235,"start":236,"enrollment":237,"conditions":238,"interventions":241},"NCT00453804","Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI)",[62],"2007-06","2006-07",15,[239,17,240,19],"Bipolar Disorders","Schizoaffective Disorders",[242,243],"injectable naltrexone","oral naltrexone",{"trials":245,"activeCount":70},[],{"intervention":247,"totalTrials":175,"cells":248},"Rabies Vaccine",{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":255,"PHASE4":257,"NA":283},{"trials":250,"activeCount":70},[],{"trials":252,"activeCount":70},[],{"trials":254,"activeCount":70},[],{"trials":256,"activeCount":70},[],{"trials":258,"activeCount":70},[259,273],{"nctId":260,"briefTitle":261,"status":190,"phases":262,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":269},"NCT02564471","Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.",[62],"2018-08","2019-02","2016-11-11",103,[268],"Rabies",[270,271,272,247],"Chloroquine","Atovaquone and Proguanil","Doxycycline",{"nctId":274,"briefTitle":275,"status":190,"phases":276,"primaryCompletion":277,"completion":277,"start":278,"enrollment":279,"conditions":280,"interventions":281},"NCT02374814","Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis",[62],"2016-09-22","2015-03-24",60,[268],[282],"Rabies vaccine",{"trials":284,"activeCount":70},[],{"intervention":286,"totalTrials":66,"cells":287},"Preserved saline in reconstitution of Botox",{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":296,"NA":308},{"trials":289,"activeCount":70},[],{"trials":291,"activeCount":70},[],{"trials":293,"activeCount":70},[],{"trials":295,"activeCount":70},[],{"trials":297,"activeCount":70},[298],{"nctId":299,"briefTitle":300,"status":190,"phases":301,"primaryCompletion":302,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":307},"NCT03698409","Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine.",[62],"2019-08-01","2019-01-01",68,[306],"Chronic Migraine, Headache",[286],{"trials":309,"activeCount":70},[],{"intervention":311,"totalTrials":66,"cells":312},"Varenicline",{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":334},{"trials":314,"activeCount":70},[],{"trials":316,"activeCount":70},[],{"trials":318,"activeCount":70},[],{"trials":320,"activeCount":70},[],{"trials":322,"activeCount":70},[323],{"nctId":324,"briefTitle":325,"status":190,"phases":326,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":333},"NCT00727103","Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia",[62],"2011-05","2008-07",10,[17,331,19,332],"Schizoaffective Disorder","Nicotine Dependence",[311],{"trials":335,"activeCount":70},[],{"intervention":337,"totalTrials":66,"cells":338},"armodafinil",{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":360},{"trials":340,"activeCount":70},[],{"trials":342,"activeCount":70},[],{"trials":344,"activeCount":70},[],{"trials":346,"activeCount":70},[],{"trials":348,"activeCount":70},[349],{"nctId":350,"briefTitle":351,"status":190,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":359},"NCT00678691","An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue",[62],"2009-06","2009-12","2007-08",55,[358],"Fibromyalgia, Primary",[337],{"trials":361,"activeCount":70},[],{"intervention":363,"totalTrials":66,"cells":364},"cyclobenzaprine ER",{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":371,"PHASE4":373,"NA":386},{"trials":366,"activeCount":70},[],{"trials":368,"activeCount":70},[],{"trials":370,"activeCount":70},[],{"trials":372,"activeCount":70},[],{"trials":374,"activeCount":70},[375],{"nctId":376,"briefTitle":377,"status":224,"phases":378,"primaryCompletion":379,"completion":379,"start":353,"enrollment":380,"conditions":381,"interventions":385},"NCT01041495","Cyclobenzaprine Extended Release (ER) for Fibromyalgia",[62],"2013-03",37,[382,25,383,384],"Fibromyalgia","Sleep","Fatigue",[363],{"trials":387,"activeCount":70},[],{"intervention":389,"totalTrials":66,"cells":390},"Gaitril",{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":399,"NA":412},{"trials":392,"activeCount":70},[],{"trials":394,"activeCount":70},[],{"trials":396,"activeCount":70},[],{"trials":398,"activeCount":70},[],{"trials":400,"activeCount":70},[401],{"nctId":402,"briefTitle":403,"status":190,"phases":404,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":411},"NCT00174850","Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction",[62],"2005-05","2004-07",30,[409,410],"Anxiety","Sexual Dysfunction",[389],{"trials":413,"activeCount":70},[],{"intervention":243,"totalTrials":66,"cells":415},{"EARLY_PHASE1":416,"PHASE1":418,"PHASE2":420,"PHASE3":422,"PHASE4":424,"NA":430},{"trials":417,"activeCount":70},[],{"trials":419,"activeCount":70},[],{"trials":421,"activeCount":70},[],{"trials":423,"activeCount":70},[],{"trials":425,"activeCount":70},[426],{"nctId":232,"briefTitle":233,"status":190,"phases":427,"completion":235,"start":236,"enrollment":237,"conditions":428,"interventions":429},[62],[239,17,240,19],[242,243],{"trials":431,"activeCount":70},[],{"intervention":270,"totalTrials":66,"cells":433},{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":442,"NA":448},{"trials":435,"activeCount":70},[],{"trials":437,"activeCount":70},[],{"trials":439,"activeCount":70},[],{"trials":441,"activeCount":70},[],{"trials":443,"activeCount":70},[444],{"nctId":260,"briefTitle":261,"status":190,"phases":445,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":446,"interventions":447},[62],[268],[270,271,272,247],{"trials":449,"activeCount":70},[],{"intervention":271,"totalTrials":66,"cells":451},{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":466},{"trials":453,"activeCount":70},[],{"trials":455,"activeCount":70},[],{"trials":457,"activeCount":70},[],{"trials":459,"activeCount":70},[],{"trials":461,"activeCount":70},[462],{"nctId":260,"briefTitle":261,"status":190,"phases":463,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":464,"interventions":465},[62],[268],[270,271,272,247],{"trials":467,"activeCount":70},[],{"intervention":272,"totalTrials":66,"cells":469},{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":476,"PHASE4":478,"NA":484},{"trials":471,"activeCount":70},[],{"trials":473,"activeCount":70},[],{"trials":475,"activeCount":70},[],{"trials":477,"activeCount":70},[],{"trials":479,"activeCount":70},[480],{"nctId":260,"briefTitle":261,"status":190,"phases":481,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":482,"interventions":483},[62],[268],[270,271,272,247],{"trials":485,"activeCount":70},[],{"intervention":487,"totalTrials":66,"cells":488},"Naltrexone or Placebo",{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":493,"PHASE3":495,"PHASE4":497,"NA":512},{"trials":490,"activeCount":70},[],{"trials":492,"activeCount":70},[],{"trials":494,"activeCount":70},[],{"trials":496,"activeCount":70},[],{"trials":498,"activeCount":70},[499],{"nctId":500,"briefTitle":501,"status":190,"phases":502,"primaryCompletion":503,"completion":503,"start":504,"enrollment":505,"conditions":506,"interventions":511},"NCT00145847","Naltrexone Treatment of Alcohol Abuse in Schizophrenia",[62],"2008-05","2003-04",90,[17,507,508,509,510],"Mental Disorders","Alcohol Abuse","Alcoholism","Alcohol-related Disorders",[487],{"trials":513,"activeCount":70},[],{"intervention":515,"totalTrials":66,"cells":516},"Pegylated Interferon and Ribavirin",{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":523,"PHASE4":525,"NA":539},{"trials":518,"activeCount":70},[],{"trials":520,"activeCount":70},[],{"trials":522,"activeCount":70},[],{"trials":524,"activeCount":70},[],{"trials":526,"activeCount":70},[527],{"nctId":528,"briefTitle":529,"status":190,"phases":530,"primaryCompletion":531,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":538},"NCT00148031","Improving Hepatitis C Treatment in Injection Drug Users",[62],"2007-03","2003-09",111,[535,536,537,509],"Hepatitis C","Liver Diseases","Drug Abuse",[515],{"trials":540,"activeCount":70},[],{"intervention":542,"totalTrials":66,"cells":543},"spironolactone",{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":548,"PHASE3":550,"PHASE4":552,"NA":566},{"trials":545,"activeCount":70},[],{"trials":547,"activeCount":70},[],{"trials":549,"activeCount":70},[],{"trials":551,"activeCount":70},[],{"trials":553,"activeCount":70},[554],{"nctId":555,"briefTitle":556,"status":557,"phases":558,"primaryCompletion":559,"completion":560,"start":561,"enrollment":70,"conditions":562,"interventions":565},"NCT00328809","Spironolactone Safety in Dialysis Patients","WITHDRAWN",[62],"2017-06-30","2019-09-24","2013-06-30",[563,564],"End Stage Renal Disease","Congestive Heart Failure",[542],{"trials":567,"activeCount":70},[],{"intervention":569,"totalTrials":66,"cells":570},"long-lasting injectable naltrexone",{"EARLY_PHASE1":571,"PHASE1":573,"PHASE2":575,"PHASE3":577,"PHASE4":579,"NA":590},{"trials":572,"activeCount":70},[],{"trials":574,"activeCount":70},[],{"trials":576,"activeCount":70},[],{"trials":578,"activeCount":70},[],{"trials":580,"activeCount":70},[581],{"nctId":582,"briefTitle":583,"status":190,"phases":584,"primaryCompletion":585,"completion":585,"start":586,"enrollment":237,"conditions":587,"interventions":589},"NCT00453609","Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI)",[62],"2008-10","2007-04",[17,331,588,19],"Bipolar Disorder",[569],{"trials":591,"activeCount":70},[],{"intervention":593,"totalTrials":66,"cells":594},"Dexmedetomidine",{"EARLY_PHASE1":595,"PHASE1":597,"PHASE2":599,"PHASE3":601,"PHASE4":616,"NA":618},{"trials":596,"activeCount":70},[],{"trials":598,"activeCount":70},[],{"trials":600,"activeCount":70},[],{"trials":602,"activeCount":70},[603],{"nctId":604,"briefTitle":605,"status":606,"phases":607,"primaryCompletion":608,"completion":609,"start":610,"enrollment":279,"conditions":611,"interventions":613},"NCT06370442","Intranasal Dexmedetomidine vs. Standard of Care for Emergency Department (ED) Procedural Sedation in the Older Adult","UNKNOWN",[61],"2025-05-31","2025-09-01","2024-06-01",[612],"Altered Mental Status",[593,614,615],"Lorazepam","Haloperidol",{"trials":617,"activeCount":70},[],{"trials":619,"activeCount":70},[],{"intervention":614,"totalTrials":66,"cells":621},{"EARLY_PHASE1":622,"PHASE1":624,"PHASE2":626,"PHASE3":628,"PHASE4":634,"NA":636},{"trials":623,"activeCount":70},[],{"trials":625,"activeCount":70},[],{"trials":627,"activeCount":70},[],{"trials":629,"activeCount":70},[630],{"nctId":604,"briefTitle":605,"status":606,"phases":631,"primaryCompletion":608,"completion":609,"start":610,"enrollment":279,"conditions":632,"interventions":633},[61],[612],[593,614,615],{"trials":635,"activeCount":70},[],{"trials":637,"activeCount":70},[],{"intervention":615,"totalTrials":66,"cells":639},{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":652,"NA":654},{"trials":641,"activeCount":70},[],{"trials":643,"activeCount":70},[],{"trials":645,"activeCount":70},[],{"trials":647,"activeCount":70},[648],{"nctId":604,"briefTitle":605,"status":606,"phases":649,"primaryCompletion":608,"completion":609,"start":610,"enrollment":279,"conditions":650,"interventions":651},[61],[612],[593,614,615],{"trials":653,"activeCount":70},[],{"trials":655,"activeCount":70},[],{"intervention":657,"totalTrials":66,"cells":658},"Namenda\u002FMemantine",{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":676,"NA":678},{"trials":660,"activeCount":70},[],{"trials":662,"activeCount":70},[],{"trials":664,"activeCount":70},[],{"trials":666,"activeCount":70},[667],{"nctId":668,"briefTitle":669,"status":190,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":237,"conditions":673,"interventions":675},"NCT00411398","A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder",[61],"2010-05","2006-12",[674],"General Anxiety Disorder, Social Anxiety Disorder",[657],{"trials":677,"activeCount":70},[],{"trials":679,"activeCount":70},[],{"intervention":681,"totalTrials":66,"cells":682},"Doxepin",{"EARLY_PHASE1":683,"PHASE1":685,"PHASE2":687,"PHASE3":689,"PHASE4":703,"NA":705},{"trials":684,"activeCount":70},[],{"trials":686,"activeCount":70},[],{"trials":688,"activeCount":70},[],{"trials":690,"activeCount":70},[691],{"nctId":692,"briefTitle":693,"status":606,"phases":694,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":701},"NCT05115136","Using Doxepin for Urticaria",[61],"2023-01-31","2023-07-01","2022-05-23",160,[700],"Urticaria",[681,702],"Diphenhydramine",{"trials":704,"activeCount":70},[],{"trials":706,"activeCount":70},[],{"intervention":702,"totalTrials":66,"cells":708},{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":715,"PHASE4":721,"NA":723},{"trials":710,"activeCount":70},[],{"trials":712,"activeCount":70},[],{"trials":714,"activeCount":70},[],{"trials":716,"activeCount":70},[717],{"nctId":692,"briefTitle":693,"status":606,"phases":718,"primaryCompletion":695,"completion":696,"start":697,"enrollment":698,"conditions":719,"interventions":720},[61],[700],[681,702],{"trials":722,"activeCount":70},[],{"trials":724,"activeCount":70},[],{"intervention":726,"totalTrials":66,"cells":727},"Drug Abilify",{"EARLY_PHASE1":728,"PHASE1":730,"PHASE2":732,"PHASE3":741,"PHASE4":743,"NA":745},{"trials":729,"activeCount":70},[],{"trials":731,"activeCount":70},[],{"trials":733,"activeCount":70},[734],{"nctId":735,"briefTitle":736,"status":190,"phases":737,"completion":405,"start":406,"enrollment":160,"conditions":738,"interventions":740},"NCT00174876","Aripiprazole as Augmentation for TRD",[60],[739],"Depression",[726],{"trials":742,"activeCount":70},[],{"trials":744,"activeCount":70},[],{"trials":746,"activeCount":70},[],{"intervention":748,"totalTrials":66,"cells":749},"tailored antiplatelet selection",{"EARLY_PHASE1":750,"PHASE1":752,"PHASE2":754,"PHASE3":767,"PHASE4":769,"NA":771},{"trials":751,"activeCount":70},[],{"trials":753,"activeCount":70},[],{"trials":755,"activeCount":70},[756],{"nctId":757,"briefTitle":758,"status":190,"phases":759,"primaryCompletion":760,"completion":760,"start":761,"enrollment":505,"conditions":762,"interventions":765},"NCT03979781","Personalized Antiplatelet Secondary Stroke PRevenTion",[60],"2023-05-09","2018-06-11",[763,764],"Ischemic Stroke","TIA",[748,766],"standard of care",{"trials":768,"activeCount":70},[],{"trials":770,"activeCount":70},[],{"trials":772,"activeCount":70},[],{"intervention":766,"totalTrials":66,"cells":774},{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":785,"PHASE4":787,"NA":789},{"trials":776,"activeCount":70},[],{"trials":778,"activeCount":70},[],{"trials":780,"activeCount":70},[781],{"nctId":757,"briefTitle":758,"status":190,"phases":782,"primaryCompletion":760,"completion":760,"start":761,"enrollment":505,"conditions":783,"interventions":784},[60],[763,764],[748,766],{"trials":786,"activeCount":70},[],{"trials":788,"activeCount":70},[],{"trials":790,"activeCount":70},[],{"intervention":792,"totalTrials":66,"cells":793},"paclitaxel poliglumex",{"EARLY_PHASE1":794,"PHASE1":796,"PHASE2":798,"PHASE3":812,"PHASE4":814,"NA":816},{"trials":795,"activeCount":70},[],{"trials":797,"activeCount":70},[],{"trials":799,"activeCount":70},[800],{"nctId":801,"briefTitle":802,"status":190,"phases":803,"primaryCompletion":804,"completion":805,"start":806,"enrollment":807,"conditions":808,"interventions":810},"NCT00660218","A Phase I\u002FII Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer",[59,60],"2016-12","2017-04","2008-03",53,[809],"Carcinoma, Squamous Cell",[792,811],"cetuximab",{"trials":813,"activeCount":70},[],{"trials":815,"activeCount":70},[],{"trials":817,"activeCount":70},[],{"intervention":811,"totalTrials":66,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":830,"PHASE4":832,"NA":834},{"trials":821,"activeCount":70},[],{"trials":823,"activeCount":70},[],{"trials":825,"activeCount":70},[826],{"nctId":801,"briefTitle":802,"status":190,"phases":827,"primaryCompletion":804,"completion":805,"start":806,"enrollment":807,"conditions":828,"interventions":829},[59,60],[809],[792,811],{"trials":831,"activeCount":70},[],{"trials":833,"activeCount":70},[],{"trials":835,"activeCount":70},[],{"intervention":837,"totalTrials":66,"cells":838},"Rapamycin",{"EARLY_PHASE1":839,"PHASE1":841,"PHASE2":843,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":840,"activeCount":70},[],{"trials":842,"activeCount":70},[],{"trials":844,"activeCount":70},[845],{"nctId":846,"briefTitle":847,"status":190,"phases":848,"primaryCompletion":849,"completion":850,"start":585,"enrollment":851,"conditions":852,"interventions":854},"NCT00779194","Prospective Study of Rapamycin for the Treatment of SLE",[60],"2015-12","2015-12-16",99,[853],"Systemic Lupus Erythematosus (SLE)",[837],{"trials":856,"activeCount":70},[],{"trials":858,"activeCount":70},[],{"trials":860,"activeCount":70},[],{"intervention":862,"totalTrials":66,"cells":863},"chromium piccolinate",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":879,"PHASE4":881,"NA":883},{"trials":865,"activeCount":70},[],{"trials":867,"activeCount":70},[],{"trials":869,"activeCount":70},[870],{"nctId":871,"briefTitle":872,"status":224,"phases":873,"primaryCompletion":874,"completion":379,"start":875,"enrollment":279,"conditions":876,"interventions":878},"NCT00759993","Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units.",[60],"2012-06","2008-09",[877,15],"Weight Gain",[862],{"trials":880,"activeCount":70},[],{"trials":882,"activeCount":70},[],{"trials":884,"activeCount":70},[],{"intervention":886,"totalTrials":66,"cells":887},"Xyrem",{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":904,"PHASE4":906,"NA":908},{"trials":889,"activeCount":70},[],{"trials":891,"activeCount":70},[],{"trials":893,"activeCount":70},[894],{"nctId":895,"briefTitle":896,"status":557,"phases":897,"primaryCompletion":898,"completion":898,"start":899,"enrollment":70,"conditions":900,"interventions":903},"NCT00330291","Xyrem for Treatment Refractory Insomnia Due to PTSD",[60],"2006-08","2005-08",[901,902],"PTSD","Anxiety, Post Traumatic",[886],{"trials":905,"activeCount":70},[],{"trials":907,"activeCount":70},[],{"trials":909,"activeCount":70},[],{"intervention":911,"totalTrials":175,"cells":912},"paclitaxel",{"EARLY_PHASE1":913,"PHASE1":928,"PHASE2":940,"PHASE3":942,"PHASE4":944,"NA":946},{"trials":914,"activeCount":70},[915],{"nctId":916,"briefTitle":917,"status":606,"phases":918,"primaryCompletion":919,"completion":920,"start":921,"enrollment":922,"conditions":923,"interventions":925},"NCT02619448","Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC",[58],"2024-07","2025-12","2014-12",12,[924],"Non-small Cell Lung Cancer",[926,927],"Carboplatin","Paclitaxel",{"trials":929,"activeCount":70},[930],{"nctId":931,"briefTitle":932,"status":190,"phases":933,"completion":934,"start":935,"enrollment":160,"conditions":936,"interventions":938},"NCT00003555","Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors",[59],"2003-05","1998-07",[937],"Unspecified Adult Solid Tumor, Protocol Specific",[939,911],"amifostine trihydrate",{"trials":941,"activeCount":70},[],{"trials":943,"activeCount":70},[],{"trials":945,"activeCount":70},[],{"trials":947,"activeCount":70},[],{"intervention":949,"totalTrials":175,"cells":950},"Dengue virus 3 Live Virus Human Challenge",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":973,"PHASE3":975,"PHASE4":977,"NA":979},{"trials":952,"activeCount":70},[],{"trials":954,"activeCount":70},[955,965],{"nctId":956,"briefTitle":957,"status":190,"phases":958,"primaryCompletion":959,"completion":959,"start":960,"enrollment":961,"conditions":962,"interventions":963},"NCT05967455","Homologous Re-infection With Dengue 1 or Dengue 3",[59],"2024-08-26","2023-10-30",9,[28],[964,949],"Dengue virus 1 Live Virus Human Challenge",{"nctId":966,"briefTitle":967,"status":190,"phases":968,"primaryCompletion":969,"completion":969,"start":970,"enrollment":961,"conditions":971,"interventions":972},"NCT04298138","Dengue 3 Human Infection Model (DENV-3)",[59],"2021-12-14","2020-08-03",[28],[949],{"trials":974,"activeCount":70},[],{"trials":976,"activeCount":70},[],{"trials":978,"activeCount":70},[],{"trials":980,"activeCount":70},[],{"intervention":939,"totalTrials":66,"cells":982},{"EARLY_PHASE1":983,"PHASE1":985,"PHASE2":991,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":984,"activeCount":70},[],{"trials":986,"activeCount":70},[987],{"nctId":931,"briefTitle":932,"status":190,"phases":988,"completion":934,"start":935,"enrollment":160,"conditions":989,"interventions":990},[59],[937],[939,911],{"trials":992,"activeCount":70},[],{"trials":994,"activeCount":70},[],{"trials":996,"activeCount":70},[],{"trials":998,"activeCount":70},[],{"intervention":1000,"totalTrials":66,"cells":1001},"rivaroxaban",{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1013,"PHASE3":1015,"PHASE4":1017,"NA":1019},{"trials":1003,"activeCount":70},[],{"trials":1005,"activeCount":70},[1006],{"nctId":1007,"briefTitle":1008,"status":224,"phases":1009,"primaryCompletion":849,"completion":849,"start":921,"enrollment":175,"conditions":1010,"interventions":1012},"NCT02058199","Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery",[59],[1011],"Gastric Bypass Status",[1000],{"trials":1014,"activeCount":70},[],{"trials":1016,"activeCount":70},[],{"trials":1018,"activeCount":70},[],{"trials":1020,"activeCount":70},[],{"intervention":964,"totalTrials":66,"cells":1022},{"EARLY_PHASE1":1023,"PHASE1":1025,"PHASE2":1031,"PHASE3":1033,"PHASE4":1035,"NA":1037},{"trials":1024,"activeCount":70},[],{"trials":1026,"activeCount":70},[1027],{"nctId":956,"briefTitle":957,"status":190,"phases":1028,"primaryCompletion":959,"completion":959,"start":960,"enrollment":961,"conditions":1029,"interventions":1030},[59],[28],[964,949],{"trials":1032,"activeCount":70},[],{"trials":1034,"activeCount":70},[],{"trials":1036,"activeCount":70},[],{"trials":1038,"activeCount":70},[],{"intervention":1040,"totalTrials":66,"cells":1041},"DVIU treated with liquid buccal mucosal graft",{"EARLY_PHASE1":1042,"PHASE1":1044,"PHASE2":1056,"PHASE3":1058,"PHASE4":1060,"NA":1062},{"trials":1043,"activeCount":70},[],{"trials":1045,"activeCount":70},[1046],{"nctId":1047,"briefTitle":1048,"status":606,"phases":1049,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":329,"conditions":1053,"interventions":1055},"NCT03061344","Liquid Buccal Mucosa Graft Urethroplasty",[59],"2019-10","2021-10","2017-02",[1054],"Urethral Stricture",[1040],{"trials":1057,"activeCount":70},[],{"trials":1059,"activeCount":70},[],{"trials":1061,"activeCount":70},[],{"trials":1063,"activeCount":70},[],{"intervention":1065,"totalTrials":66,"cells":1066},"Dengue-1 Virus-Live Virus Human Challenge",{"EARLY_PHASE1":1067,"PHASE1":1069,"PHASE2":1079,"PHASE3":1081,"PHASE4":1083,"NA":1085},{"trials":1068,"activeCount":70},[],{"trials":1070,"activeCount":70},[1071],{"nctId":1072,"briefTitle":1073,"status":190,"phases":1074,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":961,"conditions":1077,"interventions":1078},"NCT03869060","Expansion of a Dengue-1 Live Virus Human Challenge",[59],"2019-09-20","2019-03-11",[28],[1065],{"trials":1080,"activeCount":70},[],{"trials":1082,"activeCount":70},[],{"trials":1084,"activeCount":70},[],{"trials":1086,"activeCount":70},[],{"intervention":1088,"totalTrials":66,"cells":1089},"Valproic Acid",{"EARLY_PHASE1":1090,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1110,"NA":1112},{"trials":1091,"activeCount":70},[1092],{"nctId":1093,"briefTitle":1094,"status":190,"phases":1095,"primaryCompletion":1096,"completion":1097,"start":1098,"enrollment":1099,"conditions":1100,"interventions":1103},"NCT01738815","Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer",[58],"2013-05","2014-04","2011-12",43,[1101,1102],"Hematuria","Bladder Cancer",[1088],{"trials":1105,"activeCount":70},[],{"trials":1107,"activeCount":70},[],{"trials":1109,"activeCount":70},[],{"trials":1111,"activeCount":70},[],{"trials":1113,"activeCount":70},[],{"intervention":1115,"totalTrials":66,"cells":1116},"amiloride",{"EARLY_PHASE1":1117,"PHASE1":1128,"PHASE2":1130,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1118,"activeCount":70},[1119],{"nctId":1120,"briefTitle":1121,"status":224,"phases":1122,"primaryCompletion":1123,"completion":1123,"start":1124,"enrollment":26,"conditions":1125,"interventions":1127},"NCT01733680","Amiloride Hydrochloride as an Effective Treatment for ADHD",[58],"2015-09","2012-09",[1126],"ADHD",[1115],{"trials":1129,"activeCount":70},[],{"trials":1131,"activeCount":70},[],{"trials":1133,"activeCount":70},[],{"trials":1135,"activeCount":70},[],{"trials":1137,"activeCount":70},[],{"intervention":926,"totalTrials":66,"cells":1139},{"EARLY_PHASE1":1140,"PHASE1":1146,"PHASE2":1148,"PHASE3":1150,"PHASE4":1152,"NA":1154},{"trials":1141,"activeCount":70},[1142],{"nctId":916,"briefTitle":917,"status":606,"phases":1143,"primaryCompletion":919,"completion":920,"start":921,"enrollment":922,"conditions":1144,"interventions":1145},[58],[924],[926,927],{"trials":1147,"activeCount":70},[],{"trials":1149,"activeCount":70},[],{"trials":1151,"activeCount":70},[],{"trials":1153,"activeCount":70},[],{"trials":1155,"activeCount":70},[],{"intervention":1157,"totalTrials":66,"cells":1158},"Bupivacaine",{"EARLY_PHASE1":1159,"PHASE1":1172,"PHASE2":1174,"PHASE3":1176,"PHASE4":1178,"NA":1180},{"trials":1160,"activeCount":70},[1161],{"nctId":1162,"briefTitle":1163,"status":190,"phases":1164,"primaryCompletion":1165,"completion":1166,"start":1167,"enrollment":1168,"conditions":1169,"interventions":1171},"NCT04494880","Marcaine Post-Operative Pain Study",[58],"2022-12-01","2022-12-31","2020-12-09",22,[1170],"Effect of Drug",[1157],{"trials":1173,"activeCount":70},[],{"trials":1175,"activeCount":70},[],{"trials":1177,"activeCount":70},[],{"trials":1179,"activeCount":70},[],{"trials":1181,"activeCount":70},[],{"intervention":1183,"totalTrials":66,"cells":1184},"Ketamine",{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1191,"PHASE4":1193,"NA":1195},{"trials":1186,"activeCount":70},[],{"trials":1188,"activeCount":70},[],{"trials":1190,"activeCount":70},[],{"trials":1192,"activeCount":70},[],{"trials":1194,"activeCount":70},[],{"trials":1196,"activeCount":70},[1197],{"nctId":1198,"briefTitle":1199,"status":190,"phases":1200,"primaryCompletion":353,"completion":353,"start":1201,"enrollment":1202,"conditions":1203,"interventions":1205},"NCT00614159","Ketamine Compared to Propofol for Pediatric GI Endoscopy",[],"2007-10",34,[1204],"Endoscopy",[1183,1206],"Propofol",{"intervention":1206,"totalTrials":66,"cells":1208},{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1215,"PHASE4":1217,"NA":1219},{"trials":1210,"activeCount":70},[],{"trials":1212,"activeCount":70},[],{"trials":1214,"activeCount":70},[],{"trials":1216,"activeCount":70},[],{"trials":1218,"activeCount":70},[],{"trials":1220,"activeCount":70},[1221],{"nctId":1198,"briefTitle":1199,"status":190,"phases":1222,"primaryCompletion":353,"completion":353,"start":1201,"enrollment":1202,"conditions":1223,"interventions":1224},[],[1204],[1183,1206],{"intervention":1226,"totalTrials":66,"cells":1227},"Aprotinin",{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1229,"activeCount":70},[],{"trials":1231,"activeCount":70},[],{"trials":1233,"activeCount":70},[],{"trials":1235,"activeCount":70},[],{"trials":1237,"activeCount":70},[],{"trials":1239,"activeCount":70},[1240],{"nctId":1241,"briefTitle":1242,"status":190,"phases":1243,"primaryCompletion":353,"completion":353,"start":1244,"enrollment":1245,"conditions":1246,"interventions":1248},"NCT00617955","Effects of Aprotinin During Cardiac Surgery\u002FLong Term Death Rates",[],"2007-09",462,[1247],"Cardiac Surgery",[1226,1249],"Amicar",{"intervention":1249,"totalTrials":66,"cells":1251},{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1256,"PHASE3":1258,"PHASE4":1260,"NA":1262},{"trials":1253,"activeCount":70},[],{"trials":1255,"activeCount":70},[],{"trials":1257,"activeCount":70},[],{"trials":1259,"activeCount":70},[],{"trials":1261,"activeCount":70},[],{"trials":1263,"activeCount":70},[1264],{"nctId":1241,"briefTitle":1242,"status":190,"phases":1265,"primaryCompletion":353,"completion":353,"start":1244,"enrollment":1245,"conditions":1266,"interventions":1267},[],[1247],[1226,1249],{"intervention":1269,"totalTrials":66,"cells":1270},"Dexamethasone",{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1277,"PHASE4":1279,"NA":1281},{"trials":1272,"activeCount":70},[],{"trials":1274,"activeCount":70},[],{"trials":1276,"activeCount":70},[],{"trials":1278,"activeCount":70},[],{"trials":1280,"activeCount":70},[],{"trials":1282,"activeCount":70},[1283],{"nctId":1284,"briefTitle":1285,"status":224,"phases":1286,"primaryCompletion":849,"completion":849,"start":1287,"enrollment":203,"conditions":1288,"interventions":1292},"NCT01397552","Dexamethasone Versus Depo Medrol in Lumbar Epidurals",[63],"2009-09",[1289,1290,1291],"Lumbar Spine Disc Herniation","Lumbar Radiculitis","Lumbar Back Pain",[1269,1293],"methylprednisolone acetate",{"intervention":1293,"totalTrials":66,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1302,"PHASE4":1304,"NA":1306},{"trials":1297,"activeCount":70},[],{"trials":1299,"activeCount":70},[],{"trials":1301,"activeCount":70},[],{"trials":1303,"activeCount":70},[],{"trials":1305,"activeCount":70},[],{"trials":1307,"activeCount":70},[1308],{"nctId":1284,"briefTitle":1285,"status":224,"phases":1309,"primaryCompletion":849,"completion":849,"start":1287,"enrollment":203,"conditions":1310,"interventions":1311},[63],[1289,1290,1291],[1269,1293],{"intervention":1313,"totalTrials":66,"cells":1314},"Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain",{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1321,"PHASE4":1323,"NA":1325},{"trials":1316,"activeCount":70},[],{"trials":1318,"activeCount":70},[],{"trials":1320,"activeCount":70},[],{"trials":1322,"activeCount":70},[],{"trials":1324,"activeCount":70},[],{"trials":1326,"activeCount":70},[1327],{"nctId":1328,"briefTitle":1329,"status":1330,"phases":1331,"conditions":1332,"interventions":1333},"NCT01918514","The Effect of Adding Magnesium Sulfate to Standard Epidural and Interscalene Block in Treatment of Patients With Chronic Pain","NO_LONGER_AVAILABLE",[],[25],[1313],{"intervention":1335,"totalTrials":66,"cells":1336},"Acamprosate",{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1345,"NA":1347},{"trials":1338,"activeCount":70},[],{"trials":1340,"activeCount":70},[],{"trials":1342,"activeCount":70},[],{"trials":1344,"activeCount":70},[],{"trials":1346,"activeCount":70},[],{"trials":1348,"activeCount":70},[1349],{"nctId":1350,"briefTitle":1351,"status":190,"phases":1352,"primaryCompletion":354,"completion":354,"start":1353,"enrollment":1354,"conditions":1355,"interventions":1356},"NCT00591565","An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants",[63],"2006-06",13,[409],[1335],{"intervention":1358,"totalTrials":66,"cells":1359},"50 mg naltrexone",{"EARLY_PHASE1":1360,"PHASE1":1362,"PHASE2":1364,"PHASE3":1366,"PHASE4":1368,"NA":1370},{"trials":1361,"activeCount":70},[],{"trials":1363,"activeCount":70},[],{"trials":1365,"activeCount":70},[],{"trials":1367,"activeCount":70},[],{"trials":1369,"activeCount":70},[],{"trials":1371,"activeCount":70},[1372],{"nctId":1373,"briefTitle":1374,"status":190,"phases":1375,"primaryCompletion":1376,"completion":1376,"start":1377,"enrollment":66,"conditions":1378,"interventions":1379},"NCT05100563","Participant(s) With Autism and High Pain Tolerance Treated With High Dose Naltrexone",[],"2021-05-24","2018-10-01",[21],[1358],{"intervention":1381,"totalTrials":66,"cells":1382},"decolonization",{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1389,"PHASE4":1391,"NA":1393},{"trials":1384,"activeCount":70},[],{"trials":1386,"activeCount":70},[],{"trials":1388,"activeCount":70},[],{"trials":1390,"activeCount":70},[],{"trials":1392,"activeCount":70},[],{"trials":1394,"activeCount":70},[1395],{"nctId":1396,"briefTitle":1397,"status":557,"phases":1398,"primaryCompletion":1399,"completion":1399,"start":1399,"enrollment":70,"conditions":1400,"interventions":1402},"NCT01229553","Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients",[63],"2011-01",[1401],"Cystic Fibrosis",[1381],{"intervention":1404,"totalTrials":66,"cells":1405},"bisphosphonate therapy",{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1412,"PHASE4":1414,"NA":1416},{"trials":1407,"activeCount":70},[],{"trials":1409,"activeCount":70},[],{"trials":1411,"activeCount":70},[],{"trials":1413,"activeCount":70},[],{"trials":1415,"activeCount":70},[],{"trials":1417,"activeCount":70},[1418],{"nctId":1419,"briefTitle":1420,"status":224,"phases":1421,"primaryCompletion":585,"completion":585,"start":1422,"enrollment":11,"conditions":1423,"interventions":1425},"NCT00145704","Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density",[63],"2002-06",[1424],"Osteopenia",[1404]]